B Lymphocyte Stimulator-specific Inhibitor [EPC] - N0000182637

Pharmacologic Code	N0000182637
Pharmacologic Name	B Lymphocyte Stimulator-specific Inhibitor
Pharmacologic Uses	B-Lymphocyte stimulator (BLyS)-specific inhibitor
Pharmacologic Concept	Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description	An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions: A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication. A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

The table contains 3 products whose active ingredient are classified under the same pharmacologic class B Lymphocyte Stimulator-specific Inhibitor [EPC].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	49401-088	Benlysta	Non-Proprietary Name: Belimumab	Solution	Subcutaneous	Glaxosmithkline Llc	ACTIVE
	49401-101	Benlysta	Non-Proprietary Name: Belimumab	Injection, Powder, Lyophilized, For Solution	Intravenous	Glaxosmithkline Llc	ACTIVE
	49401-102	Benlysta	Non-Proprietary Name: Belimumab	Injection, Powder, Lyophilized, For Solution	Intravenous	Glaxosmithkline Llc	ACTIVE